Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Rebimastat (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Jan 2013 Actual end date Jul 2006 added as reported by ClinicalTrials.gov.
- 06 Jul 2007 New trial record.